Akebia Therapeutics, Inc. develops and commercializes therapeutics for people impacted by kidney disease. Company news commonly covers Vafseo® (vadadustat), an oral HIF-PH inhibitor indicated for anemia due to chronic kidney disease in adults receiving dialysis, and Auryxia® (ferric citrate), a U.S.-marketed therapy for chronic kidney disease-related conditions.
Recurring updates also address product revenue, dialysis-market access, clinical data publications, and kidney disease pipeline programs, including praliciguat in focal segmental glomerulosclerosis, AKB-097 in rare kidney diseases, and AKB-9090 for cardiac surgery-associated acute kidney injury. Akebia also reports Nasdaq inducement grants, board changes, investor presentations, and quarterly financial results.
Akebia Therapeutics (Nasdaq: AKBA) has launched the VOCAL trial, a post-marketing study for its FDA-approved anemia treatment Vafseo® (vadadustat). The study, conducted in partnership with DaVita clinics, will evaluate the benefits of three-times-weekly Vafseo dosing compared to standard erythropoiesis-stimulating agents (ESA) in dialysis patients.
The trial will enroll approximately 350 patients across 18 DaVita hemodialysis clinics for up to 33 weeks. The study includes a sub-study of 28 patients to analyze red blood cell quality. Primary endpoints focus on hemoglobin changes, while secondary endpoints include serious adverse events, target hemoglobin achievement, and RBC transfusion requirements.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has granted stock options to four new employees as employment inducements. The options total 238,500 shares with an exercise price of $3.69 per share, matching the closing price on July 31, 2025.
The options will vest over a 4-year period, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter. These 10-year term options were granted under Nasdaq Listing Rule 5635(c)(4) and are subject to continued employment with Akebia.
Akebia Therapeutics (Nasdaq: AKBA) has scheduled the release of its second quarter 2025 financial results for Thursday, August 7, 2025, before market open. The company will host a conference call at 8:00 a.m. EDT on the same day to discuss the results and recent business developments.
Participants are encouraged to register in advance and join the call 15 minutes early to ensure timely connection. The presentation will be accessible via live webcast through Akebia's investor relations website, with an archived version available for later viewing.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease treatments, has announced its participation in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference. Chief Commercial Officer Nik Grund will engage in a Fireside Chat on Monday, July 14 at 10:00 AM EDT.
Investors and interested parties can access the presentation recording through the Investors section of Akebia's website at ir.akebia.com after the conference concludes.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has granted stock options to four newly-hired employees as employment inducements. The options total 141,800 shares of common stock with an exercise price of $3.64 per share, matching the closing price on June 30, 2025.
The options will vest over a four-year period, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. Each option has a 10-year term and follows Akebia's inducement award program guidelines and Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics (NASDAQ: AKBA), a biopharmaceutical company focused on kidney disease treatments, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's executive management will engage in a Fireside Chat scheduled for June 5, 2025, at 8:45 AM EDT in New York City. Investors and interested parties can access the webcast presentation through Akebia's investor relations website at ir.akebia.com after the conference concludes. The conference will run from June 3-5, 2025.
Akebia Therapeutics (AKBA) announced three upcoming poster presentations at the 62nd European Renal Association Congress 2025, taking place June 4-7 in Vienna. The presentations will focus on clinical data for vadadustat, their treatment for CKD-related anemia. Key presentations include: a cardiovascular safety analysis of vadadustat in dialysis patients presented by Dr. Glenn Chertow, a study on vadadustat's combination with ferric citrate, and real-world data comparing HIF-PH inhibitors with ESAs in non-dialysis CKD patients from a Japanese database study.
Akebia Therapeutics (NASDAQ: AKBA), a biopharmaceutical company focused on kidney disease treatments, has announced its participation in the upcoming H.C. Wainwright 3rd Annual BioConnect Investor Conference. The company's CEO John Butler and CCO Nik Grund will engage in a Fireside Chat on Tuesday, May 20, 2025, at 2:30 PM EDT at the Nasdaq Headquarters in New York City. Investors can access the presentation webcast through the "Investors" section of Akebia's website after the conference.